Clinical trials: Muscle Spasticity
Spasticity, Multiple Sclerosis
Phase 3, 28-week, Randomized, Double-blind, Placebo-controlled Safety and Efficacy Study of Nabiximols as an add-on Therapy in Subjects With Spasticity Due to Multiple Sclerosis.
The purpose of this study is to determine the effective dose range and to demonstrate a non-effective dose range of Sativex compared with placebo in relieving symptoms of spasticity due to multiple sclerosis.
- Trial name
- NCT01868048
- Testing
- Sativex
- Sponsor
- GW Research Ltd
Muscle Spasticity
Meditoxin® Treatment in Patients With Post Stroke Upper Limb Spasticity
Botulinum Toxin for the Treatment of Post Stroke Upper Limb Spasticity.
- Trial name
- NCT02757404
- Testing
- Ultrasonography guidance injection of Meditoxin®., Electrical stimulation guidance injection of Meditoxin®., Manual needle placement injection of Meditoxin®.
- Volunteers
- 59 people
- Sponsor
- Medy-Tox
Muscle Spasticity
To Document the Effectiveness of BoNT-A Injection in Adult Subjects With Upper Limb Spasticity Following Stroke
The purpose of the study is to assess the responder rate as defined by the achievement of the primary goal from the Goal Attainment Scale following one BoNT-A injection cycle in accordance with routine practices.
- Trial name
- ULIS2 (NCT01020500)
- Where
- 96 sites in Australia, Austria and 20 more
- Volunteers
- 469 people
- Sponsor
- Ipsen
Lower Limb Spasticity Due to Cerebral Palsy
Dose-response Study of Efficacy and Safety of Botulinum Toxin Type A to Treat Spasticity of the Leg(s) in Cerebral Palsy
The purpose of this study is to determine whether injections of Botulinum toxin type A into muscles of the leg(s) are effective in treating children/adolescents (age 2-17 years) with increased muscle tension/uncontrollable muscle…
- Trial name
- NCT01893411
- Testing
- IncobotulinumtoxinA (16 Units per kg body weight), IncobotulinumtoxinA (12 Units per kg body weight), IncobotulinumtoxinA (4 Units per kg body weight)
- Where
- 53 sites in Austria, Czechia and 12 more
- Volunteers
- 311 people
- Sponsor
- Merz Pharmaceuticals GmbH
Spasticity
Study Assessing Adult Subjects Affected With Upper and/or Lower Limb Spasticity Treated With Botulinum Neurotoxin Type A
The aim of the study is to describe the long term use of Botulinum Neurotoxin Type A (BoNT-A) in adult subjects affected with upper and/or lower limb spasticity who received treatment with BoNT-A for a minimum of three injections…
- Trial name
- RESULT (NCT04340336)
- Where
- 3 sites in Italy
- Volunteers
- 150 people
- Sponsor
- Ipsen
Pediatrics, Muscle Spasticity
BOTOX® Treatment in Pediatric Lower Limb Spasticity
This study will evaluate the safety and efficacy of BOTOX® (botulinum toxin Type A) in pediatric patients with lower limb spasticity.
- Conditions
- Pediatrics, Muscle Spasticity, Cerebral Palsy
- Trial name
- NCT01603628
- Testing
- botulinum toxin Type A
- Where
- 53 sites in United States, Hungary and 7 more
- Volunteers
- 384 people
- Sponsor
- Allergan
Post Stroke Upper Limb Spasticity
To Evaluate HU-014 in the Treatment of Post Stroke Upper Limb
Investigational Product: LIZTOX inj 100unit(HU-014) Title : Multi Center, Phase III Clinical Trial to Evaluate the efficacy and Safety of LIZTOX Inj in the Treatment of Post Stroke Upper Limb Spasticity Sites and investigators …
- Trial name
- HU-014 (NCT05289921)
- Testing
- HU-014 Inj
- Where
- South Korea
- Volunteers
- 198 people
- Sponsor
- Huons Co., Ltd.
Blepharospasm, Torticollis
MDs on Botox Utility (MOBILITY)
The MOBILITY Project is a prospective, non-randomized, observational, multi-centre evaluation of Health Utility via the SF-12® Health Survey Scores and the SF-6D in patients receiving BOTOX® for therapeutic use.
- Conditions
- Blepharospasm, Torticollis, Strabismus, Muscle Spasticity
- Trial name
- NCT00535938
- Testing
- botulinum toxin type A
- Where
- Canada
- Volunteers
- 1,372 people
- Sponsor
- Allergan
Spasticity, Muscle
Validation of the Spasticity Related Quality of Life Questionnaire
The purpose of the study is to describe the psychometric properties (validity, reliability and responsiveness) of the SQOL-6D instrument in the context of routine clinical treatment of upper limb spasticity.
- Trial name
- SQOL-6D (NCT03442660)
- Testing
- Data collection
- Where
- 8 sites in United Kingdom
- Volunteers
- 104 people
- Sponsor
- Ipsen
Spasticity, Muscle
MEDITOXIN® Treatment in Subjects With Post-Stroke Upper Limb Spasticity
This study is "A Prospective, Multi-center, Single Arm, Open-label, Phase IV Clinical Trial to Evaluate the Efficacy and Safety of MEDITOXIN® in Treatment of Post Stroke Upper Limb Spasticity".
- Trial name
- NCT03908580
- Testing
- Meditoxin
- Volunteers
- 120 people
- Sponsor
- Medy-Tox
Multiple Sclerosis
Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis
To evaluate the efficacy of three doses of XP19986 (arbaclofen placarbil) compared to placebo for the treatment of spasticity in subjects with multiple sclerosis (MS).
- Trial name
- NCT01359566
- Testing
- Arbaclofen placarbil 15 mg BID, Arbaclofen placarbil 30 mg BID, Arbaclofen placarbil 45 mg BID
- Where
- 28 sites in United States
- Volunteers
- 228 people
- Sponsor
- XenoPort, Inc.
Spasticity, Muscle, Microcephaly
Melpida: Recombinant Adeno-associated Virus (Serotype 9) Encoding a Codon Optimized Human AP4M1 Transgene (hAP4M1opt)
MELPIDA is proposed for the treatment of subjects with SPG50 and targets neuronal cells to deliver a fully functional human AP4M1 cDNA copy via intrathecal injection to counter the associated neuronal loss.
- Conditions
- Spasticity, Muscle, Microcephaly, Intellectual Deficiency, Growth Retardation
- Trial name
- NCT05518188
- Testing
- MELPIDA
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Elpida Therapeutics SPC
Multiple Sclerosis
A Study to Evaluate the Efficacy of Sativex in Relieving Symptoms of Spasticity Due to Multiple Sclerosis
The purpose of this study was to assess the efficacy of Sativex in relieving symptoms of spasticity in multiple sclerosis
- Trial name
- NCT01599234
- Testing
- Sativex
- Where
- United Kingdom
- Volunteers
- 337 people
- Sponsor
- Jazz Pharmaceuticals
Muscle Spasticity
Spasticity Registry Evaluating Epidemiology, Treatment Patterns and Clinical Needs
This study will examine the epidemiology (incidence and control of a disease), burden, clinical need, and treatment patterns of spasticity in patients with a diagnosis of Cerebral Palsy (CP), Multiple Sclerosis (MS), Stroke…
- Trial name
- STRETCh (NCT02145650)
- Testing
- No Intervention
- Where
- United States
- Sponsor
- Allergan
Pediatrics, Muscle Spasticity
BOTOX® Open-Label Treatment in Pediatric Upper Limb Spasticity
This study will evaluate the long-term safety of BOTOX® (botulinum toxin Type A) for the treatment of pediatric upper limb spasticity.
- Conditions
- Pediatrics, Muscle Spasticity, Cerebral Palsy, Stroke
- Trial name
- NCT01603615
- Testing
- Botulinum Toxin Type A
- Where
- 48 sites in United States, Canada and 7 more
- Volunteers
- 220 people
- Sponsor
- Allergan
Arm Spasticity
Comparing Lower-concentration Dysport Treatment Targeted to the Neuromuscular Junction With Current Clinical Practice
The aim of the study was to compare Dysport treatment results (as assessed by Modified Ashworth Scale (MAS) in the elbow joint 4 weeks post treatment) following two treatment techniques: the current clinical practice injection…
- Trial name
- NMJ (NCT01682148)
- Testing
- Botulinum toxin type A
- Where
- 23 sites in Denmark, Finland and 2 more
- Volunteers
- 100 people
- Sponsor
- Ipsen
Muscle Spasticity Due to Multiple Sclerosis
Efficacy of 5 Weeks of Treatment With BGG492 in Patients With Spasticity Due to Multiple Sclerosis
To evaluate efficacy and safety of BGG492 versus placebo on moderate to severe spasticity due to multiple sclerosis
- Trial name
- NCT01649050
- Testing
- BGG492
- Sponsor
- Novartis Pharmaceuticals
Muscle Spasticity, Stroke
Long-Term Study of OnabotulinumtoxinA Treatment in Adult Patients With Upper Limb Spasticity
This is a long-term safety and efficacy study of onabotulinumtoxinA in poststroke patients with upper limb spasticity.
- Trial name
- NCT02145689
- Testing
- onabotulinumtoxinA
- Sponsor
- Allergan
Spasticity
Study of Intramuscular Injections of OnabotulinumtoxinA to Assess Change in Disease Activity in Pediatric Participants With Spasticity Associated With Cerebral Palsy
Spasticity is often observed as muscle tightness and stiffness in the upper and/or lower limbs. Upper limb spasticity can interfere with joint movement and its severity can range from mild to severe.
- Trial name
- NCT06150729
- Where
- 8 sites in Mexico
- Volunteers
- 107 people
- Sponsor
- AbbVie
Stroke, Muscle Spasticity
Study of Responsiveness of Seven Functional Tasks in Patients With Poststroke Upper Limb Spasticity With Botulinum Toxin Type A Treatment
This study evaluates the responsiveness of 7 functional tasks to botulinum toxin Type A treatment in poststroke patients with spasticity of the upper-limb flexors
- Trial name
- NCT00651690
- Testing
- Botulinum Toxin Type A
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Allergan